Show simple item record

dc.contributor.authorSachdeva, A
dc.contributor.authorGouge, J
dc.contributor.authorKontovounisios, C
dc.contributor.authorNikolaou, S
dc.contributor.authorAshworth, A
dc.contributor.authorLim, K
dc.contributor.authorChong, I
dc.date.accessioned2020-11-03T15:25:13Z
dc.date.issued2020-06-23
dc.identifier.citationCancers, 2020, 12 (6)
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4208
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers12061665
dc.description.abstractKlotho was first discovered as an anti-ageing protein linked to a number of age-related disease processes, including cardiovascular, renal, musculoskeletal, and neurodegenerative conditions. Emerging research has also demonstrated a potential therapeutic role for Klotho in cancer biology, which is perhaps unsurprising given that cancer and ageing share similar molecular hallmarks. In addition to functioning as a tumour suppressor in numerous solid tumours and haematological malignancies, Klotho represents a candidate therapeutic target for patients with these diseases, the majority of whom have limited treatment options. Here, we examine contemporary evidence evaluating the anti-neoplastic effects of Klotho and describe the modulation of downstream oncogenic signalling pathways, including Wnt/β-catenin, FGF, IGF1, PIK3K/AKT, TGFβ, and the Unfolded Protein Response. We also discuss possible approaches to developing therapeutic Klotho and consider technological advances that may facilitate the delivery of Klotho through gene therapy.
dc.formatElectronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleKlotho and the Treatment of Human Malignancies.
dc.typeJournal Article
dcterms.dateAccepted2020-06-16
rioxxterms.versionofrecord10.3390/cancers12061665
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-06-23
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancers
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Ashworth Collaborators
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Ashworth Collaborators
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNot known
icr.researchteamAshworth Collaboratorsen_US
dc.contributor.icrauthorChong, Yu-Shingen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0